Patient Summary: The study of tamoxifen and raloxifene (STAR): Initial findings from the NSABP P-2 breast cancer prevention study

Carolyn Vachani, RN, MSN, AOCN
Abramson Cancer Center of the University of Pennsylvania
Ultima Vez Modificado: 9 de junio del 2006

Share article


The study of tamoxifen and raloxifene (STAR): Initial findings from the NSABP P-2 breast cancer prevention study

The STAR trial included post-menopausal women with a high risk of developing breast cancer (Gail model risk 1.66%). Women were randomized to receive tamoxifen 20mg daily for 5 years or raloxifene 60mg daily for 5 years.

Tamoxifen and raloxifene were found to be equally effective in reducing the rate of invasive breast cancer (163 cases of invasive breast cancer in the tamoxifen group versus 168 in the raloxifene group), compared to the predicted rate of invasive cancers with no treatment of 312 cases. Tamoxifen did decrease the rate of non-invasive breast cancers more than raloxifene (57 cases in the Tam group vs. 81 cases in the Ral group).

There were fewer blood clots in the group receiving raloxifene. Although not statistically significant, there were 40% fewer endometrial cancers in the raloxifene arm (36 cases in the Tam group, 23 in the Ral group). There were also fewer cases of cataracts in the raloxifene arm. There were no significant differences in any other invasive cancers, cardiac events, osteoporotic fractures, or deaths.

In postmenopausal women at high risk for developing breast cancer, raloxifene and tamoxifen are equally effective at reducing the incidence of invasive breast cancer, but tamoxifen was more effective at reducing the incidence of non-invasive breast cancer. In deciding which agent to choose for preventing breast cancer in high-risk postmenopausal women, these factors can be considered:

    • Prior hysterectomy (risk of endometrial cancer)
    • Acceptance of risk of non-invasive breast cancer
    • Risk of thromboembolic events (blood clots) (the study patients were highly selected to have low risk)
    • Side-effect profiles of tamoxifen and raloxifene
    • Cost


News
Study finds no association in early-stage breast cancer patients on adjuvant tamoxifen

Apr 19, 2010 - Despite a strong biologic rationale, there may be no association between concomitant usage of cytochrome P450 2D6 inhibitors such as selective serotonin reuptake inhibitors and breast cancer recurrence in patients with early-stage disease who are treated with adjuvant tamoxifen, though there is an association between poor tamoxifen adherence and increased risk of breast cancer events, according to a study published online April 12 in the Journal of Clinical Oncology.



I Wish You Knew

How cancer patients have changed my life

View More



Blogs and Web Chats

OncoLink Blogs give our readers a chance to react to and comment on key cancer news topics and provides a forum for OncoLink Experts and readers to share opinions and learn from each other.




OncoLink OncoPilot

Frente a un nuevo diagnóstico de cáncer o de cambiar el curso de su tratamiento actual? Deje que nuestro personal de enfermería cáncer que ayudan a pasar!

Más información